Hints and tips:
Related Special Reports
...Other drugmakers could still “win” the race in the rapidly growing obesity market dominated by Novo Nordisk and Eli Lilly, according to the chief executive of biotech company Zealand Pharma....
...David Ricks, Eli Lilly’s chief executive, said under a draft plan to cut market exclusivity protection from 10 to eight years, it might not be worth the industry pursuing treatments for chronic diseases...
...Eli Lilly and Vertex declined to comment on the talks....
...Eli Lilly said that it plans to submit the results to the US Food and Drug Administration and other medicine regulators worldwide to seek approval for tirzepatide as a sleep apnoea treatment beginning this...
...The addition of Amazon Pharmacy to Eli Lilly’s direct-to-consumer dispensing network is the first time Amazon has partnered with a big drug company since it launched its online pharmacy business in 2020....
...Dear reader, It isn’t often that a company pays good money to criticise customers for buying its product. But that is what Eli Lilly did this week....
...Developed respectively by Novo Nordisk and Eli Lilly, they are now being prescribed to millions of people....
...BSP previously produced Covid antibody treatment bamlanivimab for Eli Lilly....
...Patients on the donanemab study had more advanced Alzheimer’s than patients on similar studies, Eli Lilly said....
...Demand for a new class of diabetes and obesity drugs will boost US drugmaker Eli Lilly’s sales by 20 per cent in 2024, pushing its revenues above $40bn, the company said on Tuesday....
...High demand for weight-loss drugs has helped Novo Nordisk become Europe’s largest company by market capitalisation, while Eli Lilly overtook Johnson & Johnson as the world’s largest pharmaceutical company...
...The retail giant struck a deal earlier this month to dispense medication on behalf of Zepbound maker Eli Lilly’s direct-to-consumer service LillyDirect....
...Ricks said Lilly “will make it abundantly clear to Catalent that we plan to enforce our contract with them to the letter”....
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...Mounjaro will become available “within weeks” in Great Britain for treatment of both diabetes and obesity, after the medicines regulator authorised US pharma company Eli Lilly on Thursday to sell the weight...
...Eli Lilly lowered its expectations for full-year earnings because of accounting charges related to recent acquisitions, despite beating expectations in the third quarter driven by growth in diabetes and...
...David Risinger, a Leerink analyst, said in a note on Wednesday that the company had designed its pricing to encourage coverage in employers’ health insurance plans....
...Indianapolis-based Eli Lilly, meanwhile, has become the world’s largest pharmaceutical company on the back of sales of its drug Mounjaro for diabetes and strong trial results for its use in weight loss....
...This is a very small deal for a company as big as Eli Lilly. The drugs giant is riding high on diabetes drug Mounjaro, which has potential use as a weight-loss treatment....
...The US federal drug regulator has approved Eli Lilly’s injectable diabetes medication for weight loss, as demand for the blockbuster treatments continues to surge....
...Eli Lilly, the world’s largest drugmaker, plans to bolster its portfolio of cancer drugs by buying Point Biopharma for $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price....
...Hassabis stated the goal days after announcing Isomorphic Lab’s first two pharmaceutical partnerships with Eli Lilly and Novartis, which came to a combined value of up to $3bn, in deals set to transform...
...Both Leqembi and Eli Lilly’s new drug donanemab target amyloid, a toxic protein that builds up in the brain, usually before significant levels of tau develop....
...They include the popular new diabetes and weight-loss drugs Ozempic and Wegovy, made by Novo Nordisk, and Mounjaro and Zepbound made by Eli Lilly....
International Edition